EBS Emergent BioSolutions Inc

  1. Stocks
  2. Healthcare
  3. NYSE: EBS

Price (delayed)

$1.9

Market cap

$99.19M

P/E Ratio

N/A

Dividend/share

N/A

EPS

-$14.85

Enterprise value

$847.69M

Emergent BioSolutions is a global life sciences company whose mission is to protect and enhance life. Through their specialty products and contract development and manufacturing services, the company is dedicated ...

Highlights
Emergent BioSolutions's debt has decreased by 39% YoY
EBS's EPS is up by 2.4% since the previous quarter
EBS's equity has dropped by 53% year-on-year and by 7% since the previous quarter
EBS's quick ratio is down by 29% YoY
Sector: Healthcare
Industry: Drug Manufacturers - Specialty & Generic
Website: http://www.emergentbiosolutions.com
Peers: MRK SIGA CMRX XOMA

Key stats

What are the main financial stats of EBS
Market
Shares outstanding
52.2M
Market cap
$99.19M
Enterprise value
$847.69M
Valuations
Price to earnings (P/E)
N/A
Price to book (P/B)
0.15
Price to sales (P/S)
0.09
EV/EBIT
N/A
EV/EBITDA
N/A
EV/Sales
0.81
Earnings
Revenue
$1.05B
EBIT
-$643.3M
EBITDA
-$518.2M
Free cash flow
-$257.9M
Per share
EPS
-$14.85
Free cash flow per share
-$5.04
Book value per share
$12.51
Revenue per share
$20.49
TBVPS
$24.54
Balance sheet
Total assets
$1.82B
Total liabilities
$1.17B
Debt
$860.2M
Equity
$649.3M
Working capital
$28.2M
Liquidity
Debt to equity
1.32
Current ratio
1.04
Quick ratio
0.46
Net debt/EBITDA
-1.44
Margins
EBITDA margin
-49.4%
Gross margin
32.8%
Net margin
-72.5%
Operating margin
-69.2%
Efficiency
Return on assets
-34.4%
Return on equity
-86.8%
Return on invested capital
-41.9%
Return on capital employed
-54.9%
Return on sales
-61.3%
Dividend
Dividend yield
N/A
DPS
N/A
Payout ratio
N/A

EBS stock price

How has the Emergent BioSolutions stock price performed over time
Intraday
-2.56%
1 week
-14.8%
1 month
-22.45%
1 year
-83.77%
YTD
-20.83%
QTD
-24.9%

Financial performance

How have Emergent BioSolutions's revenue and profit performed over time
Revenue
$1.05B
Gross profit
$343.9M
Operating income
-$726.4M
Net income
-$760.5M
Gross margin
32.8%
Net margin
-72.5%
EBS's gross profit is down by 19% year-on-year and by 4.7% since the previous quarter
EBS's gross margin is down by 14% YoY
The company's revenue fell by 6% YoY and by 4.9% QoQ
Emergent BioSolutions's net margin has decreased by 3.3% QoQ

Growth

What is Emergent BioSolutions's growth rate over time

Valuation

What is Emergent BioSolutions stock price valuation
P/E
N/A
P/B
0.15
P/S
0.09
EV/EBIT
N/A
EV/EBITDA
N/A
EV/Sales
0.81
EBS's EPS is up by 2.4% since the previous quarter
The price to book (P/B) is 92% lower than the 5-year quarterly average of 1.8 and 50% lower than the last 4 quarters average of 0.3
EBS's equity has dropped by 53% year-on-year and by 7% since the previous quarter
The P/S is 95% below the 5-year quarterly average of 1.8 and 70% below the last 4 quarters average of 0.3
The company's revenue fell by 6% YoY and by 4.9% QoQ

Efficiency

How efficient is Emergent BioSolutions business performance
EBS's return on equity is down by 19% since the previous quarter
The company's return on assets fell by 13% QoQ
EBS's ROIC is down by 3.7% QoQ
EBS's ROS is down by 2.5% since the previous quarter

Dividends

What is EBS's dividend
DPS
N/A
Dividend yield
N/A
Payout ratio
N/A

There are no recent dividends present for EBS.

Financial health

How did Emergent BioSolutions financials performed over time
The total assets is 55% more than the total liabilities
The total assets has contracted by 42% YoY and by 3.7% from the previous quarter
The company's total liabilities fell by 34% YoY
Emergent BioSolutions's debt is 32% higher than its equity
EBS's equity has dropped by 53% year-on-year and by 7% since the previous quarter
Emergent BioSolutions's debt has decreased by 39% YoY

All financial data is based on trailing twelve months (TTM) periods - updated quarterly, unless otherwise specified.